VYNE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
VYNE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, VYNE Therapeutics's enterprise value is $-55.40 Mil. VYNE Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $-29.26 Mil. Therefore, VYNE Therapeutics's EV-to-EBITDA for today is 1.89.
The historical rank and industry rank for VYNE Therapeutics's EV-to-EBITDA or its related term are showing as below:
During the past 9 years, the highest EV-to-EBITDA of VYNE Therapeutics was 2.32. The lowest was -24.15. And the median was 0.09.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-11), VYNE Therapeutics's stock price is $2.67. VYNE Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $-7.279. Therefore, VYNE Therapeutics's PE Ratio for today is At Loss.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for VYNE Therapeutics's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics Annual Data | |||||||||||||||||||
Trend | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | ||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | -1.23 | -0.99 | -0.33 | 0.65 | 2.06 |
VYNE Therapeutics Quarterly Data | ||||||||||||||||||||
Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 0.65 | 0.64 | 0.22 | 0.07 | 2.06 |
For the Biotechnology subindustry, VYNE Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, VYNE Therapeutics's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where VYNE Therapeutics's EV-to-EBITDA falls into.
VYNE Therapeutics's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | -55.395 | / | -29.259 | |
= | 1.89 |
VYNE Therapeutics's current Enterprise Value is $-55.40 Mil.
VYNE Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-29.26 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VYNE Therapeutics (NAS:VYNE) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
VYNE Therapeutics's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 2.67 | / | -7.279 | |
= | At Loss |
VYNE Therapeutics's share price for today is $2.67.
VYNE Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.279.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of VYNE Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Patrick G Lepore | director | 17-17 ROUTE 208 N, FAIRLAWN NJ 07410 |
Mutya Harsch | officer: Chief Legal Officer and GC | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Tyler Zeronda | officer: Interim CFO | C/O VYNE THERAPEUTICS, 520 U.S. HIGHWAY 22, SUITE 204, BRIDGEWATER NJ 08807 |
Andrew Saik | officer: Chief Financial Officer | 640 LEE ROAD, CHESTERBROOK PA 19087 |
Rex Bright | director | 5641 LAKE VISTA DRIVE, BONSALL CA 92003 |
Iain Stuart | officer: Chief Scientific Officer | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
David Domzalski | director, officer: President and CEO | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Matthew T. Wiley | officer: Chief Commercial Officer | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLTZMAN ST, WEIZMANN SCIENCE PARK, REHOVOT L3 7670402 |
Anthony D Bruno | director | C/O WARNER CHILCOTT HOLDINGS CO., LTD., 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866 |
Stanley Hirsch | director | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Ilan Hadar | officer: CFO and Country Manager | C/O FOAMIX PHARMACEUTICALS LTD., 2 HOLZMAN STREET, WEIZMANN SCIENCE PARK, REHOVOT L3 76704 |
Sharon Surrey Barbari | director | 280 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | director, 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By sperokesalga sperokesalga • 05-18-2023
By Value_Insider Value_Insider • 12-07-2022
By Marketwired • 10-30-2023
By Value_Insider Value_Insider • 12-02-2022
By GuruFocusNews GuruFocusNews • 06-27-2022
By Marketwired • 11-07-2023
By Stock market mentor Stock market mentor • 01-09-2023
By Value_Insider Value_Insider • 12-12-2022
By sperokesalga sperokesalga • 04-19-2023
By GuruFocusNews GuruFocusNews • 07-05-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.